The contribution of experimental microsurgery to medicine development: The history of world-first agonist medicine development with S1P receptor functions

Prologue The role of academia in terms of developing medicine in our country is highly advanced. However, the academia-industry infrastructural improvement for clinical development has not reached to some extent; world-class. I have been involved in the research for new and innovative immunosuppressive agent for a long time thanks to the fact that I have extended research method of preclinical models based on surgical technology. One of them is S1P agonist medicine. Fingolimod (FTY720) is phosphorylated in vivo and acts as S1P receptor. S1P as physiologically active agent releases lymphocyte from lymph nodes by combining with S1P1 receptor on lymphocyte. Nevertheless, phosphorylated FTY720 merged into S1P1 receptor, the emerging rate of receptor with S1P decreases and results in the isolation of lymphocyte in the lymph nodes. Consequently the lymphocyte is not invasive in allograft inflammation and the immunoregulative strength is considered to be active. Experimental microsurgery technique is indispensable for generating organ transplant models of small animals. The technique has been developed as a means of academic research method, on the contrary, at medicine development corporations they focus on the toxicity test at GLP facilities rather than generating models for the effectiveness experiments. The reason is that appropriate technical instructions for acquiring experimental microsurgery technique is not available at medicine development corporations. The technical development of experimental microsurgery should be disseminated in collaboration between academia and corporation. The summary describes the features of development so far. I hope it acts as a basic information for many researchers who take academia-industry collaboration into consideration.